Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma

Authors :: Ross S. Berkowitz
Colleen M. Feltmate
Ursula A. Matulonis
Panagiotis A. Konstantinopoulos
Neal I. Lindeman
Elizabeth H. Stover
Source :: JCO Precision Oncology. :1-8
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.

Subjects :: 0301 basic medicine
Cancer Research
business.industry
DNA sequencing
03 medical and health sciences
Serous fluid
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Ovarian carcinoma
Cancer research
Medicine
business
Estrogen receptor alpha

Full Text Access

Tools